Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIO NASDAQ:CDXS NASDAQ:GERN NASDAQ:IRWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$20.65-3.8%$18.93$8.72▼$27.41$569.11M1.21237,870 shs419,766 shsCDXSCodexis$2.77+0.7%$2.30$0.96▼$3.87$251.79M2.521.82 million shs995,385 shsGERNGeron$1.25$1.50$1.04▼$2.01$801.90M0.6816.32 million shs11.57 million shsIRWDIronwood Pharmaceuticals$3.57-0.8%$3.79$0.56▼$5.78$582.12M0.293.72 million shs2.03 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma+3.27%+6.13%-10.39%+77.58%-97.20%CDXSCodexis+4.17%+8.70%-2.48%+172.28%+18.03%GERNGeron-0.79%-0.79%-17.22%-25.60%-13.79%IRWDIronwood Pharmaceuticals-2.96%-6.49%-14.29%+5.26%+507.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$20.65-3.8%$18.93$8.72▼$27.41$569.11M1.21237,870 shs419,766 shsCDXSCodexis$2.77+0.7%$2.30$0.96▼$3.87$251.79M2.521.82 million shs995,385 shsGERNGeron$1.25$1.50$1.04▼$2.01$801.90M0.6816.32 million shs11.57 million shsIRWDIronwood Pharmaceuticals$3.57-0.8%$3.79$0.56▼$5.78$582.12M0.293.72 million shs2.03 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma+3.27%+6.13%-10.39%+77.58%-97.20%CDXSCodexis+4.17%+8.70%-2.48%+172.28%+18.03%GERNGeron-0.79%-0.79%-17.22%-25.60%-13.79%IRWDIronwood Pharmaceuticals-2.96%-6.49%-14.29%+5.26%+507.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCrescent Biopharma 3.11Buy$28.0035.59% UpsideCDXSCodexis 2.00Hold$5.0080.51% UpsideGERNGeron 2.00Hold$2.50100.00% UpsideIRWDIronwood Pharmaceuticals 2.43Hold$6.2374.60% UpsideCurrent Analyst Ratings BreakdownLatest CDXS, GERN, IRWD, and CBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D-)5/8/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/27/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/27/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)3/12/2026CDXSCodexis Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.003/12/2026CDXSCodexis Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight3/2/2026CBIOCrescent Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $22.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCrescent Biopharma$10.84M52.50N/AN/A$6.53 per share3.16CDXSCodexis$70.39M3.58N/AN/A$0.48 per share5.77GERNGeron$183.88M4.36N/AN/A$0.36 per share3.47IRWDIronwood Pharmaceuticals$361.51M1.61$0.25 per share14.41($1.33) per share-2.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCrescent Biopharma-$153.94M-$10.91N/AN/AN/AN/A-103.44%-88.19%7/30/2026 (Estimated)CDXSCodexis-$43.97M-$0.37N/AN/AN/A-40.97%-68.09%-23.72%8/12/2026 (Estimated)GERNGeron-$83.50M-$0.11N/A12.50N/A-35.48%-23.31%-10.08%8/5/2026 (Estimated)IRWDIronwood Pharmaceuticals$24.02M$0.605.95N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)Latest CDXS, GERN, IRWD, and CBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CDXSCodexis-$0.11-$0.10+$0.01-$0.10$14.53 million$15.25 million5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million5/6/2026Q1 2026GERNGeron-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 million4/29/2026Q1 2026CBIOCrescent Biopharma-$0.85-$0.70+$0.15-$0.70$0.36 million$1.04 million3/11/2026Q4 2025CDXSCodexis$0.01$0.11+$0.10$0.11$35.83 million$38.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCrescent BiopharmaN/AN/AN/AN/AN/ACDXSCodexisN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCrescent BiopharmaN/A13.7813.78CDXSCodexis0.945.365.23GERNGeron0.526.784.96IRWDIronwood PharmaceuticalsN/A1.411.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCrescent Biopharma75.19%CDXSCodexis78.54%GERNGeron73.71%IRWDIronwood PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCBIOCrescent Biopharma4.00%CDXSCodexis3.50%GERNGeron1.71%IRWDIronwood Pharmaceuticals9.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCrescent Biopharma5027.56 million26.46 millionNo DataCDXSCodexis25090.90 million87.72 millionOptionableGERNGeron70641.52 million630.55 millionOptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableCDXS, GERN, IRWD, and CBIO HeadlinesRecent News About These CompaniesIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 28 at 4:05 PM | businesswire.comIRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation UseMay 28 at 11:10 AM | zacks.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Pass Above 200 Day Moving Average - Here's WhyMay 28 at 3:04 AM | americanbankingnews.comIronwood, AbbVie win U.S. label expansion for Linzess in pediatric constipationMay 27 at 11:20 PM | seekingalpha.comIronwood Pharmaceuticals: A Contrarian Buy OpportunityMay 21, 2026 | seekingalpha.comIs Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?May 20, 2026 | insidermonkey.comTop 10 small‑cap value picks: lowest forward P/Es and strong profitabilityMay 18, 2026 | msn.comIronwood Pharmaceuticals, Inc: Still A Profitable OpportunityMay 16, 2026 | seekingalpha.comIronwood Pharmaceuticals: Still A Profitable OpportunityMay 16, 2026 | seekingalpha.comIronwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is DueMay 13, 2026 | seekingalpha.comIronwood Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comIronwood Pharmaceuticals (NASDAQ:IRWD) Announces Quarterly Earnings ResultsMay 9, 2026 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by Wall Street Zen to "Hold"May 9, 2026 | marketbeat.comIronwood Stock Down Despite Q1 Earnings and Revenue BeatMay 8, 2026 | zacks.comIronwood Pharmaceuticals Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comIronwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 12.3% - Here's WhyMay 7, 2026 | marketbeat.comIronwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue EstimatesMay 7, 2026 | zacks.comIronwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial GuidanceMay 7, 2026 | businesswire.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Passes Above 200 Day Moving Average - Should You Sell?May 7, 2026 | marketbeat.comIronwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)May 4, 2026 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXS, GERN, IRWD, and CBIO Company DescriptionsCrescent Biopharma NASDAQ:CBIO$20.65 -0.82 (-3.82%) Closing price 04:00 PM EasternExtended Trading$20.52 -0.13 (-0.63%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Codexis NASDAQ:CDXS$2.77 +0.02 (+0.73%) As of 04:00 PM EasternCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Geron NASDAQ:GERN$1.25 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.26 +0.01 (+0.80%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ironwood Pharmaceuticals NASDAQ:IRWD$3.57 -0.03 (-0.83%) Closing price 04:00 PM EasternExtended Trading$3.58 +0.01 (+0.28%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
